Myocardial Ischemia Market Outlook: Innovation, Diagnosis & Intervention Growth

The myocardial ischemia market, encompassing diagnostic systems (e.g. ECG, stress testing, imaging), interventional devices (stents, drug-coated balloons), and ******cological therapies, is entering a period of notable growth. Estimated at USD 12 billion in 2023, the market is forecast at USD 13 billion in 2024, expanding to nearly USD 18 billion by 2030, driven by a compound annual growth rate (CAGR) of approximately 5.5%. This trajectory presents compelling opportunities for B2B stakeholders across innovation, supply chain, and clinical service domains.

Key Market Drivers

1. Rising Cardiovascular Disease Burden
Myocardial ischemia remains a leading cause of morbidity and mortality worldwide. Aging populations and increasing prevalence of hypertension, diabetes, and obesity are driving greater demand for advanced diagnostics, interventional devices, and ischemia monitoring therapies.

2. Technological Advances in Diagnosis
Innovations in CT angiography, fractional flow reserve (FFR), cardiac MRI, and wearable ECG monitors enable earlier detection and non-invasive assessment of ischemia. Device OEMs that combine accuracy with workflow efficiency see strong adoption in cardiology practices and hospital settings.

3. Growth of Minimally Invasive Interventions
Drug-eluting stents (DES), bioresorbable scaffolds, and drug-coated balloons are increasingly used in treatment of ischemic lesions. Adoption is driven by better clinical outcomes, shorter recovery times, and expanded indication approvals—presenting opportunities for OEMs and hospital procurement teams.